Mangoceuticals, Inc.
MGRXHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Mangoceuticals, Inc. focuses on Health Information Services services and products. Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States. The company carries a $8.1M market cap, placing it firmly in the micro-cap category. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.
Market Cap
$8.1M
Beta
2.28
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-1.42
EPS (Fwd)
—
ROE
-113.9%
ROA
-60.6%
Cash
$174,562
Total Debt
$294,023
Free CF
$1.4M
52W Change
-71.1%
Annual Financials
Cash vs Debt
Where MGRX stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, MGRX finished 20.41% below its 150-day moving average ($0.49) and 54.12% below its 200-day moving average ($0.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MGRX overbought or oversold?
At the July 15, 2026 close, MGRX's RSI(14) was 57.0, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $175K in cash, though total debt stands at $294K. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $1.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -113.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $9K to $456K.
A beta of 2.28 means MGRX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MGRX.